After several months of development, and input from many sources (Patient Advocate Robin Martinez and Drs. James Hsieh, Sandy Srinivas, James Leppert), we have now released a clinical trial search tool for rare kidney cancer. Check it out and let us know what you think,
Blog
Nizar Tannir: How do I treat my patients with nccRCC?
The Kidney Cancer Association held a "Survivors' Conference" on Saturday, April 16, 2016 at MD Anderson in Houston.
The KCA also kindly recorded a video (here).
I have reproduced particular slides of interest from Nizar Tannir's nccRCC presentation below:
Determining the appropriate Kidney Cancer Treatment
So what "process" does a doctor follow to determine the appropriate treatment for kidney cancer? I asked Memorial Sloan Kettering's Dr. James Hsieh about this and he sent the attached graphic. For those without 20/40 vision, I describe the graphic here.
Clinical Trials
A discussion of the ins and outs of clinical trials is here. You can research clinical trials using the sites listed below:
RareKidneyCancer.org Site Index
Topics include FAQs, Kidney Cancer Types. Cancer Biology. and Clinical Trial Lists. A site summary indexed by "Kidney Cancer Type" is below.
James Hsieh Research
Dr. Hsieh specializes in treating kidney cancers. His laboratory primarily focuses its efforts on translational kidney cancer research.
Frequently Asked Questions
This site is meant for patients who receive a rare Kidney Cancer diagnosis and physicians who give them.
This site's information is vetted by practicing physician scientists who work in the field of rare kidney cancers.
Types of Kidney Cancer
Kidney Cancer is not just one disease. There are a number of different cell types, each of which responds somewhat differently to treatment. Dr. W.
RareKidneyCancer.org Launches
RareKidneyCancer.org launched today. It was conceived at the Kidney Cancer Association meeting in November 2015 at Miami Bay Biscayne. There, with the kind permission of the KCA organizers, we were able to approach physicians at the conference and ask one question "What is the biggest bottleneck in creating new treatments for rare kidney cancers"?
